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Abstract
Background: Few data are available on the long-term effect of pulmonary rehabilitation (PR) and on long PR
programs in interstitial lung diseases (ILD).
We aimed to evaluate the effects of PR on exercise capacity (6-Minute Walking Distance, 6MWD; Peak Work Rate,
Wmax), quality of life (St George’s Respiratory Questionnaire, SGRQ), quadriceps force (QF) and objectively measured
physical activity in ILD after the 6-month PR-program and after 1 year.
Methods: 60 patients (64 ± 11 years; 62% males; 23% with IPF) were randomly assigned to receive a 6 month-PR
program or usual medical care.
Results: Exercise capacity, quality of life and muscle force increased significantly after the program as compared to
control (mean,95%CI[ll to ul]; 6MWD + 72,[36 to 108] m; Wmax 19, [8 to 29]%pred; SGRQ − 12,[− 19 to − 6] points; QF
10, [1 to 18] %pred). The gain was sustained after 1 year (6MWD 73,[28 to 118] m; Wmax 23, [10 to 35]%pred; SGRQ
− 11,[− 18 to − 4] points; QF 9.5, [1 to 18] %pred). Physical activity did not change.
Conclusions: PR improves exercise tolerance, health status and muscle force in ILD. The benefits are maintained at
1-year follow-up. The intervention did not change physical activity.
Trial registration: Clinicaltrials.gov NCT00882817.
Background
Interstitial lung diseases (ILD) are a group of disorders
characterized by progressive dyspnoea, exercise limitation
and poor quality of life [1, 2]. Treatment typically involves
corticosteroids or cytotoxic drugs and, in some cases, anti-
fibrotic agents [3]. While these therapies tackle the re-
spiratory problems to some degree, strategies that further
reduce complaints, improve health status and delay
extra-pulmonary disease progression are therefore needed.
It has been shown that quadriceps weakness [4] and
physical inactivity [5] are present in idiopathic pulmonary
fibrosis (IPF) and poor exercise capacity, physical inactivity
and, recently, a low fat-free mass index have been related to
mortality [5–7]. Therefore, enhancing exercise tolerance,
physical activity and muscle function in IPF must be treat-
ment goals that were not shown to be altered by pharmaco-
therapy [3]. These factors have been proven to be tackled
by pulmonary rehabilitation (PR) in other chronic lung dis-
eases, such as COPD [8].
Rare randomised controlled trials exist about the
effectiveness of PR in ILD [9–13]. A Cochrane review
[14] accumulated 168 patients for the most studied out-
come measure (6-min walking distance, 6MWD) and
reported clinically significant benefits on this outcome
after short programs (8–12 weeks). A recent large
Australian trial reported somewhat smaller effects [9].
None of these studies propose long programs and only
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The aim of this study was to evaluate the feasibility
and effectiveness of a longer (6-month) multidisciplinary
PR program on exercise tolerance, muscle strength,
quality of life and physical activity in a randomized




Patients with chronic ILD referred to the ILD clinic in the
University Hospital of Leuven were considered for enrol-
ment. According to eligibility criteria, potential candidates
were informed about the protocol and written informed
consent was obtained, between March 2009 and Septem-
ber 2011. The study was approved by the local ethics com-
mittee (B32220095560) of this hospital.
Inclusion criteria were a diagnosis of ILD according to
internationally established criteria with a formal workup
and multidisciplinary discussion [1, 2], dyspnoea on exer-
tion and having a stable medical therapy with no infec-
tion/exacerbation in the previous 4 weeks.
Exclusion criteria were comorbidities (unstable angina,
recent myocardial infarction or cerebrovascular accident,
active cancer, severe orthopedic disorders) or systemic
manifestations (active myopathy, arthralgia, synovitis)
that do not allow training and a life expectancy below
3 months.
Study design
Patients were randomly assigned to the rehabilitation or
control group using sealed envelopes prepared and
shuffled before the start of the study by an independent
person unrelated to the study protocol. The envelope
was opened by the allocator sequentially, only after the
participant’s name was written on it.
Patients assigned to the rehabilitation group were
invited to attend a 6-month outpatient rehabilitation
program with a total of 60 sessions, 3 times per week for
the first 3 months and thereafter twice weekly. The pro-
gram was performed in accordance with the guidelines
[16] and is detailed in the Additional file 1 (online data
supplement). Patients assigned to the control group were
treated with maximal medical care and with an identical
medical follow-up, similarly to the active intervention
arm.
Assessments
All measurements were made at enrolment and at 3, 6
and 12 months after the start of the study.
The primary outcome of the study, functional exercise
capacity, was measured as the distance walked during
the best of two 6-minute walking tests (6MWD) [17]
and also expressed as percentage of the predicted values
[18]. Use of oxygen was standardized to a minimal flow
rate of 2 l-per-minute and subsequent follow-up tests
were conducted in the same conditions as at baseline.
The difference in 6MWD between treatment and control
group at 6 months was considered as the primary
endpoint.
The secondary outcomes were forced vital capacity
(FVC); slow vital capacity (SVC); diffusing capacity for
carbon monoxide (DLCO); arterial partial pressure of
oxygen (PaO2); maximal work rate (Wmax); 6MWD;
quadriceps (QF) and hand grip (HF) muscle force; qual-
ity of life evaluated by the the St George’s respiratory
(SGRQ) and the chronic respiratory disease question-
naires (CRQ) and dyspnoea (MRC 1 to 5). More details
on the assessments are provided in the Additional file
1 (online data supplement).
Patients were provided with an activity monitor Sense-
Wear Armband (Bodymedia, Pittsburgh, USA), in order
to assess objectively their physical activity. They were
instructed to wear the monitor for at least 7 consecutive
days, from waking up until going to bed. Days with less
than 8 h of wearing time during waking (defined as
7 AM-8 PM) were excluded. Only week days were used
to minimize the variability. A valid measurement was
defined as having at least 2 valid weekdays. The influ-
ence of the duration of the daylight time was included as
a covariate [19].
Mean step count and mean time in at least moderate
intense physical activity (MPA) were chosen as the phys-
ical activity outcomes. MPA was defined as any activity
with an energy expenditure above 3 METs [20]. The
SenseWear has been validated in COPD patients [21], a
respiratory population with a comparable inactive
lifestyle.
Physical activity at 1 year was not included in the
analysis due to the large number of missing data at this
time point, caused by incompliance of patients and tech-
nical problems. For this reason the data were not judged
as being representative of the entire sample and there-
fore not included in the analyses.
All adverse events during the rehabilitation program
were registered.
Statistics
All variables were expressed as means ± standard devi-
ation (SD) or 95% confidence interval (95% CI). A min-
imal 6MWD benefit of 38 ± 43 m might be expected
after 3 months [10]. To anticipate a similar difference of
40 ± 45 m, a sample size of 20 patients in each arm is
needed to show a statistically significant difference at the
0.05 p-level with 80% power. Anticipating on 40% of
dropouts, a total number of 60 patients were random-
ized. Statistical analysis was performed using mixed
models including the outcomes as measured in the 4
visits (baseline, after 3, 6 and 12 months). ‘Visit’ was
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included as a class variable. P values below 0.05 were
considered as significant in all analyses (R version 3.2.1)
[22]. Group, time and group*time interactions were
retrieved. This interaction term assesses the pure effect
of rehabilitation since it is the difference, at each time-
point, between changes from baseline in the
rehabilitation group and in the control group. Duration
of daylight was including as a (time varying) covariate
when investigating the physical activity outcomes [19].
The number needed to treat (NNT) to achieve an
increase in functional exercise capacity was defined as a
clinically significant improvement (> 30 m) in the
6MWD.
Results
Study recruitment and population characteristics
Figure 1 shows the Consort flow diagram. From 271
patients referred to the ILD clinic, 209 were eligible for
inclusion; 60 (22%; 37 M/23F) were randomized.
Sixty-seven percent of patients completed the rehabili-
tation program and 60% of the randomized patients
were followed up at 1 year.
Fig. 1 Consort Flow Diagram
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Table 1 shows the baseline characteristics of the par-
ticipants. At baseline, 6MWD (expressed as percentage
of the predicted value) was slightly lower (p = 0.045) and
hypersensitivity pneumonitis was more represented in the
rehabilitation group. The groups were matched for other
parameters (Table 1, Additional file 1: Table S1). Patients
who dropped out did not differ from those who com-
pleted the study in the rehabilitation group; in the
control group, drop-outs appeared to be younger and to
have worse diffusing capacity (Additional file 1: Table S2).
Effects
At 6 months, the 6MWD of the intervention group was
mean, 95% CI [ll to ul] + 72, [36 to 108]m better as
compared to the usual care group (Table 2, Fig. 2). The
benefit was largely maintained between groups at
1-year follow-up (73, [28 to 118] m). Taking a conserva-
tive intention to treat approach where none of the
dropouts in either group is counted as a responder, 11
patients (37% of the initially selected 30 patients) had a
clinically significant improvement in their 6MWD at
the 1-year time point, whereas only 5 (17%) of the
controls had such an improvement. This results in a
NNT of 5.
Similarly, the intervention yielded significant increases
in maximal exercise capacity (Wmax), health status (in all
the domains) and quadriceps force at the end of PR
(Table 2, Fig. 2, Additional file 1: Tables S3-S4), as
compared to usual care. Most of these benefits were
maintained at 1 year. A significant improvement was
already shown after 3 months of PR for exercise tolerance,
muscle force, total scores of health status, SGRQ activity
domain and CRQ dyspnoea, emotion and mastery (Table
2, Additional file 1: Tables S3-S4).
The rehabilitation program did not change MRC dys-
pnoea and physical activity significantly as compared to
the control group at any time point (Table 3, Fig. 2,
Additional file 1: Table S4).
PR did not influence lung function and arterial
blood gases with the exception of forced vital capacity
which was slightly better in the rehabilitation group
as compared to usual care (Table 2, Additional file 1:
Table S5).
Missing data
The mixed model assumes that a patient with a missing
data follows the general trend of the group. We challenged
this option by considering a more penalizing hypothesis:
in the intervention group, missing data were assumed to
follow the general trend of the control group whereas, in
the control group, missing data were assumed to be equal
to the baseline values. With this hypothesis, the PR-effect
on 6MWD, Wmax, QF and CRQ remained significant at
any time-point (Additional file 1: Table S6).
Feasibility and adverse events
The patients participated in a mean of 50 ± 13 sessions.
Aerobic training intensity for cycling started at 65 ± 8%
of the initial Wmax. Walking was initiated at 72 ± 8% of
the baseline mean 6MWD speed. These intensities were






Age (years) 64 (8) 64 (13) 0.81
Gender (men) 15 (50%) 22 (73%) 0.06
BMI (Kg/m2) 26 (5) 28 (4) 0.21
Diagnosis
IIP 10 (33%) 11 (37%) 0.79
• IPF 7 (23%) 7 (23%) 1.0
• NSIP 3 (10%) 3 (10%) 1.0
• DIP 0 1 (3%) 0.50
KNOWN CAUSES 12 (40%) 16 (53%) 0.30
• Chronic HP 4 (13%) 12 (40%) 0.02
• Asbestosis 0 1 (3%) 0.50
• Drug induced ILD 1 (3%) 1 (3%) 1.0
• CTD-ILD 7 (23%) 2 (7%) 0.14
UNCLASSIFIABLE ILD 8 (27%) 3 (10%) 0.09
Steroids 14 (47%) 15 (50%) 0.80
SVC (L) 2.6 (1.1) 2.9 (0.7) 0.35
(%pred) 77 (22) 76 (20) 0.86
DLCO (mmol.min
−1.kPa− 1) 3,4 (1,1) 4 (1,6) 0.11
(%pred) 41 (13) 45 (16) 0.30
PaO2 (mmHg) 77 (14) 76 (11) 0.71
6MWD (m) 491 (95) 462 (123) 0.32
(%pred) 79 (14) 71 (16) 0.045
Wmax (%pred) 71 (26) 61 (20) 0.10
QF (%pred) 81 (36) 78 (23) 0.70
HF (%pred) 85 (27) 89 (23) 0.61
SGRQ total (points) 40 (18) 42 (14) 0.68
Physical Activity (PA)
• Steps per day 7182 (3523) 5745 (3312) 0.12
• MPA 57 (21–158) 36 (10–130) 0.14
Data expressed as mean (SD) or numbers and MPA as geometric mean
(geometric interval): geometric mean is antilog(m) and geometric interval is
(antilog(m-SD) – antilog(m + SD)), m and SD being the mean and the standard
deviation of the log-transformed MPA, respectively. BMI body mass index, IIP
idiopathic interstitial pneumonia, IPF idiopathic pulmonary fibrosis, NSIP
nonspecific interstitial pneumonia, DIP desquamative interstitial pneumonia,
HP hypersensitivity pneumonitis, CTD-ILD connective tissue disease-related ILD,
SVC slow vital capacity, DLco diffusion capacity for carbon monoxide, PaO2
partial pressure of oxygen at breathing room air, 6MWD six-minute walking
distance, Wmax maximal workload, QF quadriceps force, SGRQ St George's
respiratory questionnaire, MPA moderate intense physical activity (dailt time
spent in activities with an intensity of at least 3 METs)a. p-values in bold
indicate a statistically significant difference between intervention and
control group
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progressed to 95 ± 17% and 106 ± 15%, respectively. The
resistance training load also increased significantly over
time (Fig. 3).
No adverse events related to the exercise training were
recorded during the PR program.
Discussion
This is the first trial showing long-term benefits (at 1-year
follow-up) after a 6-month outpatient PR program in ILD
and the first study investigating the PR-effect on object-
ively measured physical activity (PA). As hypothesized,
exercise capacity, health status and muscle force improved
significantly after PR; these benefits were maintained after
1 year in those patients that completed the program. PR
did not change the physical activity level.
The improvements in exercise capacity (6MWD) and
quality of life (total scores; symptoms and impact of
SGRQ; and dyspnea, emotion and mastery of CRQ) are
relevant, as they exceeded the minimal clinically import-
ant difference (MCID) after PR and at 1-year follow-up
(Table 2 and Additional file 1: Table S4) [23–26]. In IPF,
the MCID of the 6MWD (22–45 m) [23, 26] and the
SGRQ (5–8 points) [27] have been established [24], but,
to our knowledge, the MCID of the CRQ has not been
validated yet in ILD, only in COPD (0,5 points per item)
[25]. Clinically relevant strategies, such as pulmonary
rehabilitation, are very important for ILD patients whose
quality of life is seriously deteriorated.
Short-term benefits
To our knowledge, there are only 5 randomized controlled
trials [9–13] and a meta-analysis [14] demonstrating
improvements in exercise performance and symptoms
after exercise training in ILD. Only one non-randomised
study showed a benefit on muscle force after PR [28].
Overall, the magnitude of the effect in our trial was
more pronounced than in previous shorter studies
[10, 11, 13, 28–33].
Unfortunately, the large benefits after PR in ILD were
not translated in objective gains in PA. This is in line
with research in COPD [34]: some trials showed an
increase in PA after PR and others failed to do so. In
the negative studies, the lack of improvement was also
observed despite gains in physiological function and
health status. This is the first trial measuring the
PR-effect on PA in ILD objectively. Previously, 2 studies
[6, 35] have evaluated IPF patients with PA question-
naires and have suggested small benefits. However,
questionnaires may not provide a reliable estimation of
true PA behaviour. In our study, no specific interven-
tions were introduced to coach patients towards more
PA. Future studies could consider for instance the
Table 2 Effects of PR and at 1-year on exercise capacity, muscle
force and health status
Control Rehabilitation Rehabilitation
effect mean (95% CI ll,ul)
p- Value
6MWD (m)
Baseline 491 (57) 462 (57) 0.36
3 months 474 (57) 504 (57) 59 (33, 85) < 0.001
6 months 468 (57) 511 (57) 72 (36, 108) < 0.001
1 year 456 (57) 501 (57) 73 (28, 118) 0.002
Wmax (%pred)
Baseline 71 (18) 61 (18) 0.15
3 months 68 (18) 68 (18) 10 (2, 19) 0.01
6 months 62 (18) 71 (18) 19 (8, 29) < 0.001
1 year 61 (18) 74 (18) 23 (10, 35) < 0.001
SVC (%pred)
Baseline 77 (21) 76 (21) 0.86
3 months 77 (21) 78 (21) 2 (−2, 6) 0.23
6 months 75 (21) 77 (21) 3 (−1, 7) 0.20
1 year 76 (21) 79 (21) 4 (−0.2, 9) 0.06
DLCO (%pred)
Baseline 42 (13) 45 (13) 0.31
3 months 39 (13) 44 (13) 1.2 (− 2.4, 4.8) 0.52
6 months 39 (13) 43(13) 0.9 (−3.6, 5.3) 0.70
1 year 38 (13) 45 (13) 3.2 (−1.8, 8.2) 0.21
QF (%pred)
Baseline 81 (27) 78 (27) 0.69
3 months 81 (27) 88 (27) 10 (2, 18) 0.01
6 months 83 (27) 90 (27) 10 (1, 18) 0.02
1 year 88 (27) 94 (27) 9.5 (1, 18) 0.04
HF (%pred)
Baseline 73 (17) 76(17) 0.56
3 months 76 (17) 91 (17) 12.5 (5, 20) 0.002
6 months 75 (17) 90 (17) 12 (4, 20) 0.004
1 year 79 (17) 88 (17) 6 (−3, 15) 0.20
SGRQ total
Baseline 40 (14) 42 (14) 0.68
3 months 44 (14) 39 (14) −7 (−13, −2) 0.005
6 months 46 (14) 35 (14) −12 (−19, −6) < 0.001
1 year 45 (14) 35 (14) −11 (− 18, −4) 0.002
Data are expressed as mean (SD) from the mixed model. The rehabilitation
effect at each time point is the difference (and its 95% confidence interval)
between changes from baseline in the rehabilitation group and in the control
group. 6MWD six-minute walking distance, Wmax maximal workload, SVC slow
vital capacity, DLco diffusion capacity for carbon monoxide, QF quadriceps
force, HF handgrip force, SGRQ St George’s respiratory questionnaire. The
rehabilitation effect at each time point is the interaction term between time
points and group effects. The p-Value on the baseline line assesses differences
in baseline values, the other ones assess the effect of rehabilitation at each
time point. p-values in bold indicate a statistically significance
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provision of feedback on PA using step-counters pro-
viding promising results in COPD [36].
Feasibility
The high number of attended sessions and the high
exercise intensity reached during the training sessions
indicate that PR is feasible to be implemented in ILD in
a similar way as in COPD [8]. In the present study, ILD
patients trained alongside patients with COPD and other
chronic respiratory conditions. However, it remains a
point of attention that many patients refuse the offer for
rehabilitation and 33% dropped out during the program
although the reasons were not related to the provided
intervention.
All ILD patients used oxygen supplements per proto-
col in order to avoid desaturation [37] and all the exer-
cise tests were performed with oxygen in order to better
show the improvements related to the training [38].
Long-term benefits
The novel finding of this trial is the maintenance of the
benefits in exercise capacity, health status and muscle
force at 1 year in a subgroup of patients. So far, 5 studies
[10, 13, 15, 28, 39] have evaluated long-term effects. Only
1 randomized trial [15] did find a discrete gain in quality
of life at 1 year and one non-randomized study [39]
Table 3 Effects of PR on physical activity
Control Rehabilitation Rehabilitation















5540 (2598) 764 (− 746, 2274) 0.32
MPA
Baseline 54 (38, 78) 36 (25, 52) 0.46
3 months
44 (31, 64) 37 (26, 54) 1.3 (0.7, 2.2) 0.42
6 months
41 (29, 60) 33 (23, 48) 1.2 (0.6, 2.3) 0.57
Steps expressed as mean (SD) and MPA as geometric mean (geometric interval):
geometric mean is antilog(m) and geometric interval is (antilog(m-SD), antilog(m
+ SD)), m and SD being the mean and the SD of the log-transformed MPA,
respectively. MPA moderate intense physical activity (daily time spent in activities
with an intensity of at least 3 METs). The rehabilitation effect at each time point is
the difference (and its 95% confidence interval) between changes from baseline
in the rehabilitation group and in the control group. As computation was made
on log-transformed MPA, rehabilitation effect is expressed as a ratio (1.3 means
+ 30% in favor of rehabilitation). The p-Value on the baseline line assesses




Fig. 2 Effects of PR and at 1-year on exercise capacity, muscle force, health status, physical activity. 6-min walking distance (6MWD) (Panel a),
quadriceps force (Panel b), St-Georges respiratory questionnaire (SGRQ) (Panel c) and steps per day (Steps) (Panel d) expressed as percentage (%)
of the baseline value as a function of time. Closed circles (solid lines) and open circles (dashed lines) are the mean values and SEM at each time
points of rehabilitation and control groups, respectively. Rehabilitation and control groups were compared for rehabilitation effects at each time
points: *** p < 0.001; ** p < 0.01; * p≤ 0.05; ns p > 0.05
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showed an improvement on 6MWD and health status at
6 months.
The larger and long-term benefits in our study could
potentially be explained by the differences in the
rehabilitation program, the differences in disease aeti-
ology and disease severity.
First, our regimen proposed a longer training than
reported previously [9–13, 28–30, 32, 33, 35, 39]. In
COPD, longer programs showed to have more effects than
shorter programs [8, 40]. In addition, in line with recom-
mendations for PR [16], a multidisciplinary approach
consisting of occupational therapy, psychosocial and nu-
tritional support was offered in our program.
Second, the lower proportion of IPF patients (23% in
our trial compared to 100% [11–13] or around 50% of the
patients [9, 10] in the other 5 randomised trials) could
explain the more pronounced treatment effects. Indeed,
the magnitude of improvement following PR in IPF was
less than other ILD [10, 41, 42] or COPD [28]. However, a
mixed population reflects more the clinical reality of most
of ILD units.
Third, greater PR-benefits were described in patients
with less functional impairment [9, 10, 28]. Our patients
had better baseline 6MWD and muscle force [10, 11, 13,
28–33], whereas, the impairment in health status was
comparable [43]. In fact, one trial with a similar baseline
6MWD did find similar PR-gains [12]. However, this
remains controversial since other studies found greater
improvements in the most disabled patients [29, 39].
Finally, it is important to note that, among the im-
munosuppressive medications proposed in the majority
of non-IPF [2] and the recent recommended antifibrotic
agents in IPF [3], none of them did increase exercise
capacity, only pirfenidone has demonstrated to reduce
the decline in 6MWD [44–47]; and nintedanib [48, 49]
showed a discrete, not clinically significant, improve-
ment in quality of life in 1 of the 2 phase three trials
[49]. The fact that PR showed a large and maintained
A
B
Fig. 3 Feasability of the training. Training intensity at the Start and the End of the 6 month PR program, expressed as mean (SD). Aerobic
training: patients started the Cycling at 60% of the initial maximal workload on the cycle ergometer and the Walking at 75% of their maximal
walking speed during the initial 6-min walking test. Based on subjective Borg scale scores, the intensity was progressively increased up to 85% of
the maximal workload and up to 110% of the maximal walking speed (Dashed lines, Panel a). Resistance training: patients started the program
on a multi-gym device in 3 series of 8 repetitions at 70% of the initial 1-Repetition Maximum (1RM) load for each muscle group (chest press,
vertical traction, leg press) and this load was progressively incremented (Panel b)
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benefit on health status and exercise tolerance and with-
out any clinically meaningful side effects is of utmost
importance to ILD patients.
Natural evolution of the disease
In contrast to previous trials, our study did not show a
lung function decline over time in the whole group [9,
10]. This finding might be due to our larger amount of
non-IPF patients.
Curiously, our study showed an improvement over time
of muscle force in the entire group. Steroid therapy con-
tributes to muscle dysfunction in ILD [50], a treatment
often proposed to non-IPF patients [1, 2, 51]. In our study,
47% were under prednisolone at baseline or during the
preceding 6 months (Table 2) and only 28% at 1 year. We
suggest that muscle dysfunction of our ILD patients might
be partly explained by the steroid therapy and the im-
provement over time by the gradual steroid tapering.
Limitations
First, an a priori expected limitation of the study was the
dropout rate (33%) over the course of the 6-month PR
program. This number was slightly higher than observed
in ILD following some shorter programs [10–13, 30, 33,
39], but similar as the Australian trial [9] and long pro-
grams in COPD [8, 40]. However, since the patients who
dropped out from the rehabilitation group were very simi-
lar to those who completed the PR program, this has likely
had minimal impact on the main results of the study. In
addition, it is important to see that long-term benefits
were obtained in a significant fraction of patients in the
rehabilitation group resulting in a very acceptable NNT of
5 for the outcome 6MWD. Finally, a treatment of missing
data penalizing the PR-effect did not affect the significance
at any time-point.
Second, assessors were not blinded for 6MWD (main
outcome) which may have led to an overestimation of
the benefit, however this probably will not have affected
the results of quality of life.
Third, only 20% from the eligible candidates were ran-
domized in the present study (Fig. 1). This may com-
promise the external validity of the study. Whereas it
shows the general difficulty of performing randomised
controlled trials in rare diseases like ILD and patients
may have considerable travel distances to attend our
centre of reference. This has likely not impacted on the
observed differences between groups.
Conclusion
We conclude that a 6-month outpatient pulmonary
rehabilitation program resulted in improvements in func-
tional and maximal exercise capacity, health status and
muscle force but not in physical activity in patients with
ILD. The benefits were maintained at 1-year follow-up.
Additional file
Additional file 1: Online data supplement contains Table S1. Baseline
characteristics. Table S2. Baseline values of dropouts compared to non-
dropouts patients at 1-year. Table S3. Effects of PR and at 1-year on max-
imal exercise capacity and muscle force. Table S4. Effects of PR and at 1-
year on quality of life. Table S5. Effects of PR and at 1-year on lung func-
tion. Table S6. Effects of PR and at 1-year with penalizing treatment of
missing data. (DOCX 57 kb)
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